Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jop Mostert

Showing results (21-30 of 49) with videos related to

Pageof 5
Sort By:
European Journal of Neurology|June 12, 2023
Threshold definitions for significant change on the timed 25-foot walk and nine-hole peg test in primary progressive multiple sclerosisMarcus W Koch, Pavle Repovic, Jop Mostert, et al.
Journal of Neurology|May 15, 2022
The timed 25-foot walk is a more sensitive outcome measure than the EDSS for PPMS trials: an analysis of the PROMISE clinical trial datasetMarcus W Koch, Jop Mostert, Pavle Repovic, et al.
Multiple Sclerosis and Related Disorders|December 3, 2022
The nine hole peg test as an outcome measure in progressive MS trialsMarcus W Koch, Pavle Repovic, Jop Mostert, et al.
European Journal of Neurology|December 20, 2021
Early first-line treatment response and subsequent disability worsening in relapsing-remitting multiple sclerosisMarcus W Koch, Jop Mostert, Pavle Repovic, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|October 10, 2025
Extended window of relapse recovery in RRMS: an analysis of the DECIDE datasetJop Mostert, Eva M Strijbis, Miguel D'Haeseleer, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 21, 2019
Fluoxetine in progressive multiple sclerosis: The FLUOX-PMS trialMelissa Cambron, Jop Mostert, Marie D'Hooghe, et al.
Neurology|April 18, 2023
Longitudinal Changes in Cognitive Test Scores in Patients With Relapsing-Remitting Multiple Sclerosis: An Analysis of the DECIDE DatasetNina Castrogiovanni, Jop Mostert, Pavle Repovic, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 20, 2026
Diminishing returns of disease-modifying treatment in older participants of MS clinical trialsEva Strijbis, Jop Mostert, Miguel D'Haeseleer, et al.
Journal of Neurology|April 12, 2025
Measuring cognitive change in secondary progressive MS: an analysis of the ASCEND cognition substudyVictoria Leavitt, Jop Mostert, Jacynthe Comtois, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 9, 2024
Selecting Informative Patients for Phase 2 Progressive Trials in MS: Design Considerations for Phase 2 Clinical Trials in Progressive MSMarcus W Koch, Carlos Camara-Lemarroy, Eva Strijbis, et al.
Pageof 5

Showing results (21-30 of 49) with videos related to

Sort By:
Pageof 5
European Journal of Neurology|June 12, 2023
Threshold definitions for significant change on the timed 25-foot walk and nine-hole peg test in primary progressive multiple sclerosisMarcus W Koch, Pavle Repovic, Jop Mostert, et al.
Journal of Neurology|May 15, 2022
The timed 25-foot walk is a more sensitive outcome measure than the EDSS for PPMS trials: an analysis of the PROMISE clinical trial datasetMarcus W Koch, Jop Mostert, Pavle Repovic, et al.
Multiple Sclerosis and Related Disorders|December 3, 2022
The nine hole peg test as an outcome measure in progressive MS trialsMarcus W Koch, Pavle Repovic, Jop Mostert, et al.
European Journal of Neurology|December 20, 2021
Early first-line treatment response and subsequent disability worsening in relapsing-remitting multiple sclerosisMarcus W Koch, Jop Mostert, Pavle Repovic, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|October 10, 2025
Extended window of relapse recovery in RRMS: an analysis of the DECIDE datasetJop Mostert, Eva M Strijbis, Miguel D'Haeseleer, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 21, 2019
Fluoxetine in progressive multiple sclerosis: The FLUOX-PMS trialMelissa Cambron, Jop Mostert, Marie D'Hooghe, et al.
Neurology|April 18, 2023
Longitudinal Changes in Cognitive Test Scores in Patients With Relapsing-Remitting Multiple Sclerosis: An Analysis of the DECIDE DatasetNina Castrogiovanni, Jop Mostert, Pavle Repovic, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 20, 2026
Diminishing returns of disease-modifying treatment in older participants of MS clinical trialsEva Strijbis, Jop Mostert, Miguel D'Haeseleer, et al.
Journal of Neurology|April 12, 2025
Measuring cognitive change in secondary progressive MS: an analysis of the ASCEND cognition substudyVictoria Leavitt, Jop Mostert, Jacynthe Comtois, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 9, 2024
Selecting Informative Patients for Phase 2 Progressive Trials in MS: Design Considerations for Phase 2 Clinical Trials in Progressive MSMarcus W Koch, Carlos Camara-Lemarroy, Eva Strijbis, et al.
Pageof 5